Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

ClarisHealth Launches A.I. Powered Healthcare Fraud Detection Solution for Health Plans


ClarisHealth_logo_grey_circle_blue_aperture

ClarisHealth

Pareo Fraud Detection harnesses the power of A.I. informed by domain expertise so the SIU will get information on which providers to investigate first, why a provider is suspicious, and how valuable the investigation can be – in real-time.

ClarisHealth, the company transforming health plan operations with its comprehensive payment integrity technology platform Pareo®, launched today an artificial intelligence-based (A.I.) solution for healthcare fraud detection. Pareo Fraud Detection works seamlessly with Pareo Fraud Case Management for an integrated, 360-degree approach to mitigating fraud, waste and abuse (FWA).

According to Mark Isbitts, vice president of program integrity for ClarisHealth, who led the project, Pareo Fraud Detection provides significant advantages over conventional tools that have been in use for decades. This traditional approach involves sifting through massive amounts of data and defining thousands of rules to detect fraud, which limits its scope of effectiveness.

“Currently, the SIU deals with overwhelming numbers of false positives and manual processes and still may miss some aspects of fraudulent activity and new emerging criminal schemes,” says Isbitts. “Pareo Fraud Detection is based on our proven payment integrity technology platform and features a transparent and efficient user interface that provides a view of why a provider is marked as fraud and enables investigators to visualize different patterns and scenarios in just a few clicks – without inputting multiple rules. ”

Pareo Fraud Detection models were developed in partnership with data science experts from the College of Business Administration at the University of Illinois-Chicago (UIC). Kyle Cheek, PhD., the director of the Center for Applied Analytics and a clinical associate professor of Information and Decision Sciences at the university, has worked in various payer fraud organizations. He helped ensure the solution escaped a fundamental drawback of A.I.: lack of explainability.

“An A.I.-based technique is not usually transparent about how it generates its outputs and is often referred to as the ‘black box,’” says Cheek. “However, Pareo Fraud Detection harnesses the power of deep learning applications of A.I. informed by domain expertise so the SIU will get information on which providers to investigate first, why a provider is suspicious, and how valuable the investigation can be – in real-time, efficiently, and with limited manual efforts.”

The release of Pareo Fraud Detection continues the ClarisHealth strategic direction of expanding the native functionality of the Pareo platform to maximize health plan cost avoidance and recoveries at the most optimized cost. According to ClarisHealth CEO Jeff McNeese, this approach is termed Total Payment Integrity™ and it transforms engagement with internal and external stakeholders.

“Just like there had been little innovation in payment integrity before Pareo, the same has been true for FWA solutions,” says McNeese. “Being able to solve payment integrity and FWA challenges end-to-end – from prepay to post-pay – on a single platform fulfills the Total Payment Integrity promise of Pareo.”

For more details on the functionality of Pareo Fraud Detection and to request a personalized demonstration, please visit the website.

About ClarisHealth

ClarisHealth is the answer to the health plan industry’s siloed solutions and traditional models for identification and overpayment recovery services. ClarisHealth provides health plans and payers with total visibility into payment integrity operations through its proprietary advanced cost containment technology platform Pareo®. Pareo enables health plans to maximize avoidance and recoveries at the most optimized cost for a 10x return on their software investment. For more information please visit http://www.clarishealth.com.

Share article on social media or email:

Comagine Health Awarded Multiple New Infection Prevention Contracts


Marc Bennett, Comagine Health’s president and chief executive officer said. “By working together to protect our patients and providers from the spread of infectious disease, we can create safe care environments and enable our communities to safely reopen.”

Comagine Health, a leading national nonprofit health care consulting firm, received multiple new infection prevention contracts related to the coronavirus. The new work focuses on training, education and clinical consultation and is aimed at helping health care staff create an evidence-based approach to infection prevention during the COVID-19 pandemic.

“The coronavirus pandemic has highlighted the need for comprehensive infection prevention across the health care spectrum,” Marc Bennett, Comagine Health’s president and chief executive officer said. “By working together to protect our patients and providers from the spread of infectious disease, we can create safe care environments and enable our communities to safely reopen.”

The new contracts include:

Utah Department of Health

Comagine Health is designing and delivering a training and education collaborative for over 380 assisted living homes and intermediate care facilities. The program covers topics such as COVID-19 preparedness and management with deep dives into infection prevention strategies useful during the COVID-19 pandemic and beyond.

Washington State Department of Social and Health Services

Comagine Health will provide infection prevention training, education and consultation through an interactive, virtual learning series and direct consultation with infection prevention advisors and registered nurses. The services will be offered to over 3,200 adult family homes in Washington and will focus on advancing infection prevention and control measures in this residential care setting.

In addition to offering infection prevention services, Comagine Health is also helping communities and health care organizations respond to the pandemic using:

Contact Tracing – Comagine Health’s data-driven and community-based approach to supporting contract tracing efforts strengthens the effectiveness of this important public health tactic to control the spread of the disease.

Advanced Analytics – Through provider centered analytics, academic research and public content, Comagine Health’s advanced analytics help health care professionals see the broader impact of the COVID-19 pandemic and plan for the long term.

Telehealth and Virtual Services – Comagine Health’s training and consultation for telehealth and virtual services expand health care service delivery options, enhance access for vulnerable populations, and improve care outcomes and other clinical quality measures

Share article on social media or email:

Biorez™ Raises $3.5 Million to Close Out $7 Million in Seed Financing


News Image

Biorez, Inc., a medical device company advancing tendon and ligament repair, announced today that it has raised $3.5 million in its Series Seed financing, adding to $3.5 million raised previously. The financing round was led by New York Angels, with participation from Connecticut Innovations, Pritzker Vlock Family Office, Brainchild Holdings, and The Vertical Group.

Biorez has pioneered the BioBrace™ implant, a breakthrough material featuring a highly porous collagen sponge reinforced with bioresorbable microfilaments. The BioBrace implant is intended to augment and reinforce a wide range of tendon and ligament procedures, including rotator cuff repair and ACL reconstruction.

“Our vision is to help patients return to normal activity sooner and safer,” said Kevin Rocco, President and CEO of Biorez. “BioBrace has the potential to create a new category of implant materials known as “biocomposites” that contain both biologic and synthetic materials. This rationally-designed approach creates an opportunity for more durable surgical repairs and faster healing, which we intend to prove clinically.”

Concurrent with this financing, Biorez is also announcing the release of a new company website (http://www.biorez.com) that provides additional information about its innovative BioBrace technology.

About Biorez:

Biorez is a New Haven-based medical device start-up focused on advancing tendon and ligament repair using its proprietary BioBrace™ technology. Biorez’s products are in the development stage and have not been approved for use by any regulatory agency including the US Food and Drug Administration.

For more information email Biorez Inc. at info@biorez.com.

Share article on social media or email:

Responsum Health and Prevent Blindness Launch Innovative Glaucoma Platform


News Image

The Glaucoma Community

“While the Internet offers the promise of unlimited access to information, individuals with glaucoma can easily find themselves overwhelmed by too much content or underserved by inaccurate, inappropriate, or overly complex content. The Glaucoma Community solves that problem.”

Today, Responsum Health (Responsum), an innovative developer of personalized patient apps and chronic disease knowledge communities, and Prevent Blindness, the leading voluntary eye health and safety organization in the U.S., announced the launch of an online knowledge platform for patients with glaucoma. The platform, called The Glaucoma Community, can be accessed for free via web browser or mobile app.

Thoughtfully designed to best serve individuals with glaucoma, The Glaucoma Community provides users with a toolkit of useful, community-oriented features. The platform replaces impersonal web aggregators and social sites with a personalized Newsfeed designed to meet the needs of the user, which delivers easy-to-read summaries of important glaucoma news and information from across the internet every day. Moreover, all The Glaucoma Community content is written by professional health writers and vetted by a team of reviewers under the expert guidance of Prevent Blindness.

Other features include the Community Chat, a moderated social wall where users can share experiences and advice; automatic translation into seven languages; and the Patient One-Sheet, which allows patients to easily collect, maintain, and print their key medical information in a secure format. Members will also have access to Responsum’s robust collection of trusted patient resources, including financial assistance programs and glaucoma support groups. The Glaucoma Community was made possible by a grant from The Allergan Foundation.

Glaucoma is an eye disease that causes loss of sight by damaging a part of the eye called the optic nerve. The damage causes vision loss in patches, most frequently one’s side, or peripheral, vision. The prevalence of glaucoma increases with age. Black and Hispanic populations, as well as women in general, are also at higher risk for the disease. Glaucoma is a serious, lifelong eye disease that can lead to vision loss if not treated and controlled.

“While the Internet offers the promise of unlimited access to information, individuals with glaucoma can easily find themselves overwhelmed by too much content or underserved by inaccurate, inappropriate, or overly complex content. The Glaucoma Community solves that problem,” said Andrew M. Rosenberg, Founder and CEO of Responsum Health. “We are excited to be partnering with Prevent Blindness to bring people with glaucoma a state-of-the-art app to help them better understand their treatment options, develop strategies to improve their health and quality of life, and find community among others who are facing the same challenges from this chronic disease.”

“Today, there are an estimated 3.2 million Americans that have glaucoma,” said Jeff Todd, President and CEO of Prevent Blindness. “By creating these new resources, our goal is to provide the information and support that patients and their caregivers need to help prevent significant vision loss from the ‘Sneak Thief of Sight,’ as glaucoma is commonly called.”

About Responsum Health

Responsum Health’s mission is to build and support online knowledge communities for chronic disease patients. The company offers a free, revolutionary patient engagement platform that monitors, searches, and curates the internet to generate a personalized Newsfeed of article summaries, which are vetted by Responsum’s patient group partners. Each comprehensive platform enables patients to comment on and rate articles, as well as share them with their professional care team and loved ones. Responsum also helps patients to better organize their health information, find local patient support groups and services, and support one another through a moderated, disease-specific social wall.

About Prevent Blindness

Founded in 1908, Prevent Blindness is the nation’s leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight. Focused on promoting a continuum of vision care, Prevent Blindness touches the lives of millions of people each year through public and professional education, advocacy, certified vision screening and training, community and patient service programs and research. These services are made possible through the generous support of the American public. Together with a network of affiliates, Prevent Blindness is committed to eliminating preventable blindness in America.

For more information on glaucoma or financial assistance programs, such as Medicare coverage, please call Prevent Blindness at (800) 331-2020 or visit https://www.preventblindness.org/glaucoma.

Share article on social media or email:

Tech Executive Pratap Sarker Joins Greenway Health as President


News Image

“In my role as president, I’m eager to continue this momentum to ensure our teams and providers are happy, patients are healthy and that practices are more successful due to our simplified solutions for EHR, practice management, virtual care, billing and beyond.”

Greenway Health, a leading health information technology services provider, today announced that Pratap Sarker has been appointed president of the company. The move signifies Greenway’s continued commitment to customer success, having recently announced expanded industry collaborations and launched new health IT solutions to further support ambulatory care practices in today’s ever-changing healthcare environment.

In this newly created role, Sarker will oversee all commercial and customer-focused functions including sales, marketing and customer success. He will also work closely with Greenway’s clearinghouse, revenue cycle and IT teams to ensure the delivery of quality solutions that are critically needed to support practices’ business continuity, as well as their efforts to seamlessly provide patient care.

“As our industry continues to adjust in a post-COVID world, strategic partnerships, innovation and talent will be essential requirements for the future of healthcare practices,” said Richard Atkin, CEO of Greenway Health. “Pratap brings significant industry expertise and a focus on service, execution and collaboration. He will be an excellent addition to our leadership team in further supporting the success of our customers as they continue to serve their communities and manage COVID-19 on the front lines.”

An accomplished executive with more than 25 years of experience at leading technology organizations including IBM, Infosys, Accenture and Conduent, Sarker has achieved significant success developing teams, building lasting customer relationships and delivering services that span SaaS platforms, application services, IT infrastructure & software, analytics, artificial intelligence, consulting services and more.

“Greenway is committed to driving transformation and innovation for its ambulatory care customers and is focused on that mission every day,” said Sarker. “Since joining the company, I’ve seen firsthand how the entire team works together with passion to deliver customer success and enhance mutual trust. In my role as president, I’m eager to continue this momentum to ensure our teams and providers are happy, patients are healthy and that practices are more successful due to our simplified solutions for EHR, practice management, virtual care, billing and beyond.”

Prior to joining Greenway, Pratap served as the Group CEO of Conduent’s Commercial sector with direct responsibility for $2.5 billion in revenue. He was the business sponsor for Conduent’s 3-year transformation initiative which significantly improved business performance and profitability. He also championed the creation and implementation of Conduent’s healthcare segment strategy, which integrated technology and services with core customer processes and underlying data flows for the provider, payer and pharma verticals.

Today, Greenway’s products are used by over 55,000 providers across multiple specialties to help practices grow profitably, remain compliant, work more efficiently and improve patient outcomes. For more information on how its integrated healthcare solutions – including its new telehealth and medical billing tools – can benefit your practice, visit http://www.greenwayhealth.com.

About Greenway Health

Improving healthcare through innovation is at the heart of Greenway Health’s work. We provide electronic health record (EHR), practice management and revenue cycle management solutions that help practices in multiple specialties grow profitably, remain compliant, work more efficiently and improve patient outcomes. Our team of clinical, financial and technology experts serve as trusted advisers, committed to our customers’ success. Greenway works with over 55,000 providers across multiple specialties, which translates into millions of lives touched daily by our solutions. For details on how we can work together to build a more efficient healthcare system, visit http://www.greenwayhealth.com, call 877-537-0063, or follow Greenway on Facebook, Twitter, and LinkedIn.

Share article on social media or email:



NeoTract Designates Dr. Joanne LaMonica as UroLift® Center of Excellence


News Image

“We are proud to name Dr. Joanne LaMonica as a UroLift Center of Excellence and provider of care for men with enlarged prostate symptoms using the UroLift System treatment,” said Dave Amerson

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Joanne LaMonica, M.D., Adventist Health Ukiah in Ukiah, CA, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. LaMonica has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“We are proud to name Dr. Joanne LaMonica as a UroLift Center of Excellence and provider of care for men with enlarged prostate symptoms using the UroLift System treatment,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “The UroLift System is a safe and effective treatment that allows physicians to treat men in-office under local anesthesia, so they can experience lasting symptom relief within days after receiving treatment.”

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

# # #

For Teleflex Incorporated: Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504

nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2. McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

Know Your Rights as a Consumer Regarding Chargebacks, COVID-19 Travel Cancellations


Countless consumers have already paid via credit card for flights and hotel stays that may never happen.

This is a complex, time-consuming process and the sheer volume of cases will compound that exponentially. Over the long run, however, it will be worth the effort, in terms of both recovered revenue and sustainability.

Air travel, radically curtailed by the onset of the coronavirus pandemic, began recovering somewhat in May; however, the number of passengers passing through airport security checkpoints on the busiest day of that month amounted to only 14% of the travel volume on the equivalent day in 2019.(1) As to the hotel industry, recent research from McKinsey & Company suggests that recovery to pre-COVID-19 levels could take until 2023—or later.(2) “Much of this reduction in travel volume,” says Monica Eaton-Cardone, an entrepreneur and IT executive specializing in risk management and fraud prevention, “represents the cancellation of prepaid reservations. The industry needs to do everything it can to mitigate resulting chargeback losses.”

Underscoring the importance of this advice, says Eaton-Cardone, is the extremely serious situation facing the overall travel and hospitality sector. In May, both American Airlines and Delta announced imminent reductions in workforce through both voluntary exit programs and layoffs.(3) In early August, Hilton Worldwide Holdings announced revenue of $564 million for the second quarter, down 77.3% from the second quarter of 2019.(4)

Countless consumers, Eaton-Cardone notes, have already paid via credit card for flights and hotel stays that may never happen. Plane tickets or rooms purchased with a credit card, she points out, give the customer the option of filing a chargeback if the carrier goes under. However, in the case of multiple bankruptcies of large companies, there may be no one to whom the acquirer can pass along the bill, and acquirers have already started taking legal steps to mitigate their risk.

Tips and Rights

  • If you had to cancel a travel reservation, before you solicit a refund and/or file a claim with your credit institution, speak with the travel company. There may be options that appeal to you. Speaking directly with a company is always a good idea and should be the first step.
  • The U.S. Department of Transportation reports that airlines are obligated to offer refunds—the ticket price and any cancellation fee. If they do not, file a report with the department.
  • Every consumer has the right to dispute a credit charge—whether it’s as a result of a COVID-19 cancellation issue or not. As old-fashioned as it may sound, your best bet is to send the creditor a letter describing the dispute. Include all pertinent information and send the letter by certified mail with a return receipt. Keep all documents.
  • The Federal Trade Commission (FTC) enforces the Fair Credit Billing Act (FCBA) for most creditors—except banks. If you think a creditor has violated the FCBA, file a complaint with the FTC.

To encourage card use and retention—and wherever possible to encourage consumers with paid reservations to stay the course until normal travel resumes—some premium card issuers have announced new perks and offerings such as statement credit on select U.S. streaming video and wireless telephone services, the ability to use travel credit at gas stations and grocery stores, and the use of travel credit at restaurants.(5)

This, however, says Eaton-Cardone, probably represents more of a holding action than a solution. For airlines and hotel companies, she counsels that the best move is to prevent as many chargebacks as possible by working closely with consumers to resolve the situation. For customer disputes that do get filed, however, she says that merchants should challenge all that could be proven invalid.

“This is a complex, time-consuming process,” says Eaton-Cardone, “and the sheer volume of cases will compound that exponentially. Over the long run, however, it will be worth the effort, in terms of both recovered revenue and sustainability.”

About Monica Eaton-Cardone: 

As an acclaimed entrepreneur, speaker, and author, Monica Eaton-Cardone is widely recognized as a thought leader in the FinTech industry and a champion of women in technology. She established her entrepreneurial credentials upon selling her first business at the age of 19. When a subsequent eCommerce venture was plagued by revenue-leeching chargebacks and fraud, Eaton-Cardone rose to the challenge by developing a robust solution that combined human insight and Agile technology. Today, her innovations are used by thousands of companies worldwide, cementing her reputation as one of the payment industry’s foremost experts in risk management, chargeback mitigation, and fraud prevention. Monica Eaton-Cardone is honored to be the recipient of various industry awards. Her own expertise, as well as the services provided by her companies, have been recognized as outstanding by her peers and other industry leaders. For more information, visit  http://www.monicaec.com.  

1.    Wallace, Gregory. “Air Travel Is Bouncing Back … Sort Of.” CNN, Cable News Network, 1 June 2020, wcnn.com/2020/06/01/business/air-travel-increases/index.html.

2.    Krishnan, Vik, et al. “Hospitality and COVID-19: How Long until ‘No Vacancy’ for US Hotels?” McKinsey & Company, 10 June 2020, mckinsey.com/industries/travel-logistics-and-transport-infrastructure/our-insights/hospitality-and-covid-19-how-long-until-no-vacancy-for-us-hotels.

3.    Valinsky, Jordan, and Gregory Wallace. “American and Delta Are Preparing for Potentially Massive Layoffs.” CNN, 29 May 2020, cnn.com/2020/05/28/business/american-airlines-delta-employee-buyouts/index.html.

4.    Maake, Katishi. Bizjournals.com, bizjournals.com/washington/news/2020/08/06/hiltons-revenue-bombs-during-second-quarter.html#.

5.    The Points Guy. “Are These 9 Premium Travel Credit Cards Offering Enough Perks Amid The Coronavirus Pandemic?” Forbes, 2 June 2020, forbes.com/sites/thepointsguy/2020/06/02/are-these-9-premium-travel-credit-cards-offering-enough-perks-amid-the-coronavirus-pandemic/#753835ff637b.

Share article on social media or email:

DuPont Animal Nutrition to Partner with Proteon Pharmaceuticals in the Poultry Industry


News Image

“This technology fits with our nutribiotic approach. We are pleased to add it to our range of solutions for poultry producers.” said Aart Mateboer, business leader, DuPont Animal Nutrition.

DuPont Animal Nutrition, a business unit of DuPont Nutrition & Biosciences (DuPont), today announced a partnership with Proteon Pharmaceuticals to bring the emerging bacteriophage technology to poultry producers in selected countries, strengthening DuPont’s gut health solutions for poultry and helping to further mitigate antimicrobial resistance (AMR).

The threat of antimicrobial resistance sparked recent investment into bacteriophage technologies. Modern analytics and omics technologies have enabled screening and identification of bacteriophage candidates for a specific bacterial challenge, with significant feed and food safety implications. This emerging technology is already used in the animal food industry.

DuPont invited Proteon Pharmaceuticals to partner for their compatible work culture, solid scientific approach and leading position amongst their peers in bringing phage technology to market.

Poultry farmers in selected markets are already benefiting from using Proteon’s technology to ensure biosecurity via the waterline and to improve production efficiency.

“Proteon Pharmaceuticals is a pioneer in bacteriophage technology used in animal farming. They have been developing this technology for more than 10 years. It has been tested in Europe and Asia and proven in terms of efficacy and stability,” said Aart Mateboer, business leader, DuPont Animal Nutrition. “This technology fits with our nutribiotic approach. We are pleased to add it to our range of solutions for poultry producers.”

“We strongly believe that our technology might be considered as the future of animal health and nutrition and will help to reduce antibiotic use and antimicrobial resistance,” said Jarosław Dastych, CEO, Proteon Pharmaceuticals. “We are excited to take this next step with DuPont to bring the benefits of bacteriophage technology as a feed additive to poultry producers globally.”

DuPont Animal Nutrition is a market leader in nutritional health solutions with a comprehensive portfolio of feed enzymes, betaine, phytogenics and probiotics. Through the lens of nutribiosis, DuPont invests in science and innovation to help producers improve performance, increase liveability and support welfare in the face of increasing pressure to reduce or remove antibiotics from production systems. DuPont Animal Nutrition capabilities are underpinned by the quality and quantity of our trials, our investments in omics technologies and microbiome research, and collaboration with leading commercial, governmental and academic partners. For more information, visit http://www.animalnutrition.dupont.com

About DuPont Nutrition & Biosciences

DuPont Nutrition & Biosciences applies expert science to advance market-driven, healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. We also use cutting-edge biotechnology across a range of markets to advance bio-based solutions to meet the needs of a growing population, while protecting our environment for future generations. We are innovative solvers who help our customers turn challenges into high-value business opportunities. For more information: http://www.dupontnutritionandbiosciences.com.

About DuPont

DuPont (NYSE: DD) is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, health and wellness, food, and worker safety. More information can be found at http://www.dupont.com/.

About Proteon Pharmaceuticals

Proteon Pharmaceuticals S.A. is a leader in bacteriophage (phage) technology for livestock farming. Proteon’s products modulate the microbiome, enhancing sustainability and improving performance on the farm. We have created a precision phage development platform that uses omics technologies, molecular biology, bioinformatics and artificial intelligence (AI) to create effective, reliable and safe antibacterial solutions for animal health. Proteon was the first company to develop precision bacteriophage-based feed additives to manage bacterial challenges in poultry. More information can be found at http://www.proteonpharma.com.

Phages are the most numerous and oldest organisms on the planet. They are organic, natural and omnipresent in the environment. A critical part of the global microbiome, phages naturally protect animals and humans from bacteria.

09/09/20

DuPont™, the DuPont Oval Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted

Share article on social media or email:

Ramco Systems enables Contact Tracing and Safe Distancing at Workplace


Back To Work, Backed By Safety

…Beyond the temperature checks, sanitizers and physical distancing in seating infrastructure from a facilities management perspective, a new approach is needed to manage and monitor adherence to safe distancing protocols within the work premises and enabling contact tracing…

Amid the race to ensure workplace safety following the COVID-19 pandemic, Ramco Systems has joined forces with U.S. based Navigine and Singapore-based Hipla Technologies in enabling technology solutions to monitor and measure safe-distancing, thereby facilitating contact tracing at workplace.

While millions have adapted to working from home, there is a large percentage of essential workers needed on-site at factories, plants, offices, restaurants, e-commerce warehouses and facilities providing utilities and important services. Many organisations also see the need for office workers to return at least intermittently in split shifts while logging in remotely some of the time.

As an immediate response to the pandemic, Ramco Systems had augmented their existing facial recognition-based attendance, RamcoGEEK with thermal screening, to enable touchless experience. Sensing the urgent need for holistic contact tracing and safe distancing approaches to ensure workplace health and safety, Ramco Systems has partnered with two start-ups –- U.S. based start-up Navigine and Singapore-based Hipla Technologies to leverage Real-Time Location System (RTLS) and CCTV-based Artificial Intelligence to detect safe-distancing violations within the workplace, enabling necessary health and safety protocols aligned with organizational policies.

In partnership with Hipla, Ramco will leverage CCTV-based videos to detect safe-distancing violations crowd density controls and enable contact tracing. This is achieved by running advanced AI algorithms offered both on cloud as well as on premise models. In places where CCTV is not available, RamcoGEEK will draw upon the indoor navigation capabilities of Navigine through RTLS. The latter can pinpoint the exact location of the employee in real-time so as to map breaches of safe-distancing by location, time and persons contacted. This is possible by leveraging Bluetooth Low Energy (BLE)-based access cards distributed to employees which constantly relays information to the wireless IoT Gateways across the workplace.

Further to any self-declaration by an employee being diagnosed with COVID-19, the solution can alert the human resource or health and safety officer of the history of breaches and identities of those who were in close proximity to facilitate contact tracing. This would help the organization to anonymously notify the co-workers to prompt immediate testing given the incidence of risk. This will also allow identification of contaminated workspaces within the workplace to be quarantined and disinfected.

The RamcoGEEK platform integrates this information along with existing facial recognition-based attendance, thermal screening, mask detection, and context-aware pre-screening health survey data of an employee to provide a holistic view of organizational health and safety through real-time analytics and drill-down dashboards. A demonstration of RamcoGEEK’s Safe Distancing Dashboards for Workplace Health and Safety can be found here – https://www.youtube.com/watch?v=vbIaf9ptumk

“Organisations around the world are struggling with solutions to ensure safety of essential workers and facilitate gradual return to workplace for others. Sustained remote working can inhibit productivity in the long run and impact economic growth across sectors. Beyond the temperature checks, sanitizers and physical distancing in seating infrastructure from a facilities management perspective, a new approach is needed to manage and monitor adherence to safe distancing protocols within the work premises and enabling contact tracing. Ramco’s partnership with Hipla Technologies and Navigine revolves around this holistic approach to ensure to bring workers back to their workplaces safely. We have to ensure the workplace is a trusted environment in terms of health and safety” said Virender Aggarwal, CEO, Ramco Systems.

Sandeep Kaul, CEO, Hipla Technologies Pte Ltd, said, “We are pleased to have partnered with Ramco and Navigine to provide a one-stop workplace safety solution for companies to ensure the safety of their employees and customers. Businesses should not have to suffer additional friction when conducting business during a pandemic.”

Alexey Panyov, CEO, Navigine, said, “This is a significant breakthrough for us, and a win for all businesses that cannot operate remotely. We believe that this innovative solution will provide the much-needed solution to restore employee confidence in coming back to the workplace safely.”

About Hipla Technologies Pte Ltd.:

Hipla is a global provider of SaaS based workplace automation solutions. We harness the power of advanced artificial intelligence, big data and computer vision to create intelligent systems which enable Smart Access to premises and automates workplace safety & compliance. Our products are used by a multitude of partners to provide a contactless & seamless visitor experience while maintaining a safe and healthy workplace for users. We specialise in building intuitive IOT products which make the workplace smarter, safer and more secure

About Navigine:

Navigine is a global provider of integrated positioning technologies that enable advanced wayfinding and tracking solutions, with over 1000 implementations worldwide. We assist developers and system integrators to create mobile apps and integrated enterprise systems for people navigation as well as asset and vehicles tracking. We deliver an indoor positioning system platform with one of the best total cost of ownership for our technology partners. Navigine is continuously performing R&D activities to stay on the technology edge and develop new products with large potential and rapid scalability. Our technology partners use these products to create applications for multiple industries: Retail, Travel, Automotive, Logistics, Digital, etc. Major advantages are high accuracy, quick solution deployment, simple management and integration with external solutions

About Ramco Systems:

Ramco is a next-gen enterprise software player disrupting the market with its multi-tenant cloud and mobile-based enterprise software in HR and Global Payroll, ERP and M&E MRO for Aviation. Part of the USD 1 billion Ramco Group, Ramco Systems focuses on Innovation and Culture to differentiate itself in the marketplace. On the Innovation front, Ramco has been focusing on moving towards Active ERP leveraging Artificial Intelligence and Machine Learning by building features such as Talk It – which allows transactions to be carried out by simple voice commands, Bot it – which allows users to complete transactions using natural conversations; Mail It – transact with the application by just sending an email; HUB It – a one screen does it all concept built to address all activities of a user; Thumb It – mobility where the system presents users with option to choose rather than type values and Prompt It – a cognitive ability which will let the system complete the transaction and prompts the user for approval.

With 1800+ employees spread across 24 offices, globally, Ramco follows a flat and open culture where employees are encouraged to share knowledge and grow. No Hierarchies, Cabin-less Offices, Respect work and not titles, among others are what makes the team say, Thank God it’s Monday!

Leader in NelsonHall’s NEAT Matrix for Next Gen Payroll Services;

Winner of 2020 ISG Paragon Awards Asia Pacific, for ‘Transformation’ and ‘Collaboration’

Winner Global Payroll Transformation Project of the Year – 2019 by Global Payroll Association;

Winner of 2018 ISG Paragon Awards Australia, for ‘Best Imagination’ Award

For more information, please visit https://ramco.com/hcm/pandemic-control-system-for-workplace-safety-and-employee-health/

Follow Ramco on Twitter @ramcosystems / @ramcopayroll and stay tuned to http://blogs.ramco.com

For further information, contact:

Vinitha Ramani

+91 9840368048

vinitharamani@ramco.com

Share article on social media or email:



Summit Biomedical Imaging Signs Agreement with Theragnostics Enabling the Development of Novel Fluorescence-Based Cancer Diagnostics


This agreement with Theragnostics bolsters Summit Biomedical Imaging’s IP position with regards to PARPi-FL and will allow Summit Biomedical Imaging to focus on developing the oral cancer detection application for this molecule.

Summit Biomedical Imaging (“SBI”), a private, clinical-stage company developing products for diagnostic medical imaging and Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announce their entering into a global license agreement for intellectual property (IP) that will contribute to SBI’s global freedom to operate in the diagnostic field of certain fluorescence-labeled PARP (Poly ADP-Ribose Polymerase) inhibitors.

SBI’s cancer detection technology uses PARPi-FL, a PARP inhibitor with a fluorescence tag. PARP is a class of enzymes that are involved in normal cellular processes including DNA damage repair. PARP activity and expression are up-regulated in tumor cells. PARP inhibitors block the action of PARP by binding to PARP enzymes.

PARPi-FL combines the ability to bind to PARP with a fluorescence tag to specifically target cancers that over-express PARP. By targeting PARP, PARPi-FL brings the optical imaging agent to the cancer, enabling direct detection of tumors with significantly greater selectivity and sensitivity as compared to other competing technologies.

Andrew Riley, Chief Executive Officer of Summit Biomedical Imaging, said: “This agreement with Theragnostics bolsters Summit Biomedical Imaging’s IP position with regards to PARPi-FL and will allow Summit Biomedical Imaging to focus on developing the oral cancer detection application for this molecule. This will enable Summit Biomedical Imaging to bring new diagnostic solutions to market for detecting cancer earlier and improving patient outcomes.”

Dr. Gareth Smith, Chief Operating Officer of Theragnostics, added: “Theragnostics is pleased to work with Summit Biomedical Imaging for the development of PARP inhibitor based diagnostics. Leveraging their expertise in oncological diagnostics applications is an important step forward in implementing our strategy of bringing novel diagnostic agents and new targeted therapies to cancer patients.”

SBI’s first target for this technology is the in vivo detection of oral cancer, a large and growing market. Worldwide, over 450,000 cases of oral cancer are diagnosed each year and in many places, including the United States, the incidence rate of oral cancer is increasing. Oral cancer detection is estimated to be a $5 billion market (source, Market Research Future), which is projected to grow over 6.8% annually through 2024. Summit Biomedical Imaging seeks to enable earlier diagnosis using PARPi-FL and fluorescence imaging in the oral cavity. Earlier detection enables earlier intervention, which corresponds to saving lives and lower intervention costs, with the potential to save over $1 billion in patient and insurance costs annually.

About Summit Biomedical Imaging

Summit Biomedical Imaging is a private, clinical-stage company developing products for diagnostic medical imaging. Summit Biomedical Imaging has completed proof of concept studies for several oncological diagnostic applications. For more information, please visit http://www.summitbiomedicalimaging.com

About Theragnostics

Theragnostics, a private biotech company based in UK and US, is developing innovative radiopharmaceuticals to improve cancer diagnosis and treatment. It has developed a radiopharmaceutical technology platform that allows for diagnostic tools as well as therapeutic solutions to inform clinical management, guide care and treat cancer patients in areas of unmet medical need. Three diagnostic imaging agents have been successfully developed. The first radiopharmaceutical therapy, rPARP inhibitor THG-009 (I-123 labelled PARPi) is expected to enter clinical development in 2020. Theragnostics is led by recognized experts in the clinical development and commercialization of innovative diagnostic and therapeutic nuclear medicine products. For more information, please visit http://www.theragnostics.com.

Share article on social media or email: